A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)
Solmaz Sahebjam,Philippe L. Bedard,Vincent Castonguay,Z Chen,Michael Reedijk,Geoffrey Liu,Brenda Cohen,W-J Zhang,Blaise A. Clarke,Tong Zhang,Suzanne Kamel-Reid,Helen X. Chen,S. P. Ivy,Albiruni Ryan Abdul Razak,Amit M. Oza,E.X. Chen,Hal W. Hirte,A McGarrity,Lisa Wang,Lillian L. Siu,Sebastien J. Hotte +20 more
TL;DR: RO4929097 in combination with cediranib is generally well tolerated and preliminary evidence of antitumour efficacy with prolonged disease stabilisation in some patients with progressive malignancies warrants further clinical investigation.
Journal ArticleDOI
Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.
Martin Köbel,J Madore,Susan J. Ramus,Blaise Clarke,Paul D.P. Pharoah,Suha Deen,David D.L. Bowtell,Kunle Odunsi,Usha Menon,Carl Morrison,Shashikant Lele,Wiam Bshara,Lara Sucheston,M. W. Beckmann,Alexander Hein,Falk Thiel,A. Hartmann,David L. Wachter,Michael S. Anglesio,Estrid Høgdall,Allan Jensen,Claus Høgdall,Kimberly R. Kalli,Brooke L. Fridley,Gary L. Keeney,Zachary C. Fogarty,Robert A. Vierkant,S Liu,S Cho,Gregg Nelson,Prafull Ghatage,A Gentry-Maharaj,Simon A. Gayther,E Benjamin,Martin Widschwendter,Maria P. Intermaggio,Bruce R. Rosen,Marcus Q. Bernardini,Helen J. Mackay,Amit M. Oza,P Shaw,Mercedes Jimenez-Linan,Kristy Driver,Jennifer Alsop,Marie Mack,Jennifer M Koziak,Helen Steed,C Ewanowich,Anna deFazio,Georgia Chenevix-Trench,Sian Fereday,Bo Gao,Sharon E. Johnatty,Joshy George,Laura Galletta,Ellen L. Goode,S.K. Kjaer,David G. Huntsman,Peter A. Fasching,K. Moysich,James D. Brenton,Linda E. Kelemen +61 more
TL;DR: FOLR1-positive HGSC tumours were associated with an increased OS in the first 2 years following diagnosis, and the clinical efficacy of FOLR 1-targeted interventions should therefore be evaluated according to histology, stage and time following diagnosis.
Journal ArticleDOI
A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer.
Josep M. del Campo,Michael J. Birrer,Craig Davis,Keiichi Fujiwara,Ashwin Gollerkeri,Martin Gore,Brett E. Houk,Susie Lau,Andres Poveda,Antonio González-Martín,Carolyn Y. Muller,Kei Muro,Kristen J. Pierce,Mie Suzuki,Jennifer Vermette,Amit M. Oza +15 more
TL;DR: Gedatolisib administered by weekly intravenous infusion demonstrated acceptable tolerability and moderate activity in patients with recurrent endometrial cancer following platinum-containing chemotherapy.
Journal ArticleDOI
Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials.
TL;DR: For clinical trials that have settings with a long PPS duration and/or involve multiple rounds of postprogression therapy, a primary endpoint of PFS supported by intermediate clinical endpoints and OS may provide a more comprehensive approach for evaluating efficacy.
Journal ArticleDOI
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
Stephanie Lheureux,Stephanie Lheureux,Ana Oaknin,Swati Garg,Jeff Bruce,Ainhoa Madariaga,Neesha C. Dhani,Neesha C. Dhani,Valerie Bowering,Justin White,Sarah Accardi,Qian Tan,Marsela Braunstein,Katherine Karakasis,Iulia Cirlan,Stephanie Pedersen,Tiantiam Li,Lorena Fariñas-Madrid,Yeh Chen Lee,Zhihui Amy Liu,Trevor J. Pugh,Trevor J. Pugh,Trevor J. Pugh,Amit M. Oza,Amit M. Oza +24 more
TL;DR: This is currently the largest post-PARPi study identifying genomic mechanisms of resistance to PARPis and the activity of cediranib–olaparib varied according to the PARPi resistance mechanism.